Futureproofing [(18)F]Fludeoxyglucose manufacture at an Academic Medical Center

BACKGROUND: We recently upgraded our [(18)F]fludeoxyglucose (FDG) production capabilities with the goal of futureproofing our FDG clinical supply, expanding the number of batches of FDG we can manufacture each day, and improving patient throughput in our nuclear medicine clinic. In this paper we rep...

Descripción completa

Detalles Bibliográficos
Autores principales: Sowa, Alexandra R, Jackson, Isaac M, Desmond, Timothy J, Alicea, Jeremiah, Mufarreh, Anthony J, Pham, Jonathan M, Stauff, Jenelle, Winton, Wade P, Fawaz, Maria V, Henderson, Bradford D, Hockley, Brian G, Rogers, Virginia E, Koeppe, Robert A, Scott, Peter J H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2018
Materias:
Methodology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6173674/
https://www.ncbi.nlm.nih.gov/pubmed/30363401
http://dx.doi.org/10.1186/s41181-018-0048-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6173674/
https://www.ncbi.nlm.nih.gov/pubmed/30363401
http://dx.doi.org/10.1186/s41181-018-0048-x

Ejemplares similares